May 27, 2025, Berkeley, California
Newomics Inc., a biotechnology company specializing in mass spectrometry solutions for molecular detection, announces a strategic co-marketing and collaboration agreement with MRM Proteomics Inc., a leader in absolute quantitation of proteins and metabolites in complex biological samples using MRM technology.
This partnership represents a powerful synergy between two companies at the forefront of precision multiomics, with a shared mission to accelerate the development and deployment of advanced analytical solutions for clinical research, biomarker discovery, and drug development.
Through this collaboration, the two companies will work closely to integrate their platforms, develop co-branded applications, and jointly promote novel solutions that combine MRM Proteomics’ rigorously validated assays, kits and analytical services with Newomics’ high-performance separation and ionization tools for LC-MS-based analyses. This includes collaborative R&D, demonstration projects, and marketing initiatives targeting academic institutions, CROs, diagnostic developers, and biopharmaceutical companies across North America, Europe, and beyond.
“We are excited to partner with Newomics, whose technology perfectly complements our goal of delivering the highest standards in clinical omics through our PeptiQuant and recently developed SysQuan technology,” said Paula Jahshan, CEO of MRM Proteomics. “Together, we aim to enable our clients and collaborators to achieve deeper biological insights and faster translational outcomes by providing assays and kits for highly multiplexed, sensitive, reproducible and robust absolute quantitation for both proteins and metabolites.”
“We are excited to collaborate further with MRM Proteomics, a company at the forefront of quantitative multiomics,” said Daojing Wang, Ph.D., Founder and CEO of Newomics. “Our UniESI platform with M3 emitters and MEA chips, combined with their assays and kits, will enable accurate quantitation of peptides, proteins, and metabolites for biomarker discovery and drug development. We will showcase advances in quantitative proteomics using our joint platform at the upcoming ASMS 2025 in Baltimore.”
This agreement reflects the shared vision of both companies in advancing precision medicine by breaking down barriers to high-quality multiomics data. By combining Newomics’ engineering innovations with MRM Proteomics’ scientific and clinical expertise, the collaboration promises to empower laboratories with tools that are not only powerful and scalable but also ready for regulatory and clinical use.
Stay tuned for more updates as Newomics and MRM Proteomics roll out joint offerings, technical resources, and live demonstrations in the months ahead.
